327 related articles for article (PubMed ID: 23949878)
21. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.
Balasenthil S; Chen N; Lott ST; Chen J; Carter J; Grizzle WE; Frazier ML; Sen S; Killary AM
Cancer Prev Res (Phila); 2011 Jan; 4(1):137-49. PubMed ID: 21071578
[TBL] [Abstract][Full Text] [Related]
22. The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.
Lee JH
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625360
[TBL] [Abstract][Full Text] [Related]
23. Serum tumor markers for pancreatic cancer: the dawn of new era?
Okusaka T; Yamada T; Maekawa M
JOP; 2006 Jul; 7(4):332-6. PubMed ID: 16832130
[No Abstract] [Full Text] [Related]
24. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
25. Advances in pancreatic cancer detection.
Tanase CP; Neagu M; Albulescu R; Hinescu ME
Adv Clin Chem; 2010; 51():145-80. PubMed ID: 20857621
[TBL] [Abstract][Full Text] [Related]
26. [Differential diagnosis of pancreatic head cancer].
Kubyshkin VA; Vishnevskiĭ VA; Aĭrapetian AT; Karmazanovskiĭ GG; Kuntsevich GI; Starkov IuG
Khirurgiia (Mosk); 2000; (11):19-23. PubMed ID: 11220911
[TBL] [Abstract][Full Text] [Related]
27. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.
Nolen BM; Brand RE; Prosser D; Velikokhatnaya L; Allen PJ; Zeh HJ; Grizzle WE; Huang Y; Lomakin A; Lokshin AE
PLoS One; 2014; 9(4):e94928. PubMed ID: 24747429
[TBL] [Abstract][Full Text] [Related]
28. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
[TBL] [Abstract][Full Text] [Related]
29. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
30. Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series.
Hogendorf P; Skulimowski A; Durczyński A; Kumor A; Poznańska G; Poznańska A; Oleśna A; Rut J; Øvereng Juliebø S; Szmiel A; Strzelczyk J
Pol Przegl Chir; 2020 Apr; 92(3):32-38. PubMed ID: 32759395
[TBL] [Abstract][Full Text] [Related]
31. [Adenocarcinoma of the pancreas: are CA 19-9 assays useful?].
Lévy P
Presse Med; 2008 Jan; 37(1 Pt 2):88-94. PubMed ID: 17980545
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms.
Safi F; Schlosser W; Kolb G; Beger HG
J Gastrointest Surg; 1997; 1(2):106-12. PubMed ID: 9834336
[TBL] [Abstract][Full Text] [Related]
33. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3.
Bassi C; Salvia R; Gumbs AA; Butturini G; Falconi M; Pederzoli P
Langenbecks Arch Surg; 2002 Nov; 387(7-8):281-5. PubMed ID: 12447553
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages.
Matsumoto S; Harada H; Tanaka J; Ochi K; Seno T; Tsurumi T; Kunichika K
Pancreas; 1994 Nov; 9(6):741-7. PubMed ID: 7846018
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers in blood could help to detect pancreatic cancer.
Tanday S
Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809088
[No Abstract] [Full Text] [Related]
36. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
37. [CA 19-9 in the differential diagnosis of pancreatic lesions].
Stintzing S; Herold C; Hahn EG; Boxberger F
Internist (Berl); 2008 Feb; 49(2):225-7. PubMed ID: 18210015
[TBL] [Abstract][Full Text] [Related]
38. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]